1. Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021. https://doi.org/10.1186/s13045-021-01095-1.
2. Alphamab Oncology. Envafolimab, the world’s first subcutaneously injected PD-L1 antibody approved by NMPA! Alphamab Oncology partners with 3DMed and Simcere to innovate immunotherapy [media release]. Nov 26 2021. http://www.alphamabonc.com/en/html/news/2375.html.
3. 3D Medicines, Suzhou Alphamab. Global first IND for subcutaneous injectable anti-PD-L1 domain antibody receives FDA approval [media release]. 30 Nov 2016.
4. Ascletis. Ascletis and Alphamab announce strategic collaboration and licensing agreement for anti-PD-L1 to treat hepatitis B and other viral diseases [media release]. 13 Jan 2019.
5. Tracon Pharmaceuticals. TRACON Pharmaceuticals, 3D Medicines and Jiangsu Alphamab announce partnership for development of subcutaneous PD-L1 single-domain antibody in soft tissue sarcoma [media release]. 20 Dec 2019.